Thyroid News and Research

RSS

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its Allston, Mass., manufacturing facility and will turn over to the federal government $175 million in unlawful profits from the sale of products that were made at the plant, the U.S. Food and Drug Administration announced today.

25 May 2010

Researchers study correlation between type 2 diabetes and increased risk of cancer

Cancer and diabetes - are risk factors the same for these two diseases? Or does diabetes cause processes in the body which promote the onset or growth of cancer? It is still unclear why diabetics have a higher rate of cancer than people who are not affected by this metabolic disorder.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

AACE, AME and ETA jointly publish guidelines for diagnosis and management of thyroid nodules

Three of the world's most respected medical associations for the treatment of thyroid disease recently issued joint guidelines for the diagnosis and management of thyroid nodules. The American Association of Clinical Endocrinologists, the Associazione Medici Endocrinologi and European Thyroid Association jointly published the guidelines online this week, and the executive summary will be published in the next issue of their respective journals.

20 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Personalized treatments for thyroid disorders to be presented at ATA meeting

Internationally recognized thyroid disease experts will meet to discuss "Thyroid Disorders in the Era of Personalized Medicine" May 13 - 16 in Minneapolis, Minnesota at the American Thyroid Association's (ATA) (www.thyroid.org) Spring Meeting to be held at the Minneapolis Hyatt Regency Hotel.

11 May 2010

Having pathologist on-site during ultrasound-guided thyroid biopsies can cut down repeated biopsies

Having a pathologist on-site during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies that are often performed due to an inadequate sample from the first procedure, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

In 2009, it was estimated that a total of 22,070 new cases of brain and other CNS tumors were diagnosed. Pituitary adenomas represent one of the most common brain tumors. Large studies report that approximately 10-20 percent of the population harbors a pituitary tumor. According to the Central Brain Tumor Registry of the United States, 13.4 percent of all brain and CNS tumors diagnosed in 2009 were located in the pituitary.

4 May 2010

Whole-genome analysis may play future role in clinical medicine: Study

Scientists at Stanford and Harvard Universities collaborated to assess the clinical usefulness of analyzing a patient's full genome for disease risks and unusual drug responses. The work brings closer to reality the concept that whole-genome sequencing might one day play a clinical role.

30 Apr 2010

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it received approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer as well as Down Syndrome screening kit from the State Food and Drug Administration of China.

29 Apr 2010

Researchers to measure children with Down syndrome to develop new growth charts

Parents and doctors have known for a long time that children with Down syndrome tend to grow more slowly and are considerably shorter than most other children. But pediatricians needing to record growth milestones at regular office visits have an outdated set of growth charts based on data collected more than 25 years ago.

23 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

SNM continues to stress the need for Congress to implement long-term fix

On April 16, the President signed a bill granting temporary relief from looming cuts to Medicare reimbursement rates. Although a positive step, the medical community-along with millions of patients-continues to face significant threats to medical coverage for critical diagnostic imaging tests and therapeutics.

17 Apr 2010

Transgenic mouse model study confirms passage of maternal thyroid hormones to fetus

Until now there were only indirect evidence of the transfer of thyroid hormones from mother to fetus through the placenta during pregnancy. That event is very important because the maternal thyroid hormones appear to play a key role in the development of the nervous system and other organs of the fetus; so it's true that in case of maternal thyroid disease, such hypothyroidism, have a direct bearing on the unborn child with reduction, also significant, to its Q.I..

12 Apr 2010

Thyroid News and Research

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Researchers study correlation between type 2 diabetes and increased risk of cancer

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

AACE, AME and ETA jointly publish guidelines for diagnosis and management of thyroid nodules

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

Exelixis first-quarter revenues increase to $42.2 million

Personalized treatments for thyroid disorders to be presented at ATA meeting

Having pathologist on-site during ultrasound-guided thyroid biopsies can cut down repeated biopsies

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Whole-genome analysis may play future role in clinical medicine: Study

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

Researchers to measure children with Down syndrome to develop new growth charts

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

SNM continues to stress the need for Congress to implement long-term fix

Transgenic mouse model study confirms passage of maternal thyroid hormones to fetus

My Metabolic Makeover: Individualized nutrition program to promote overall health

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

Prague hosts 12th European Congress of Endocrinology

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

Cancer Prevention Coalition's statement on new nominated NCI Director

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News